Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
Trilaciclib (G1T28) | CDK4/6 Inhibitor | MedChemExpress
Trilaciclib dihydrochloride | C24H32Cl2N8O | CID 124081865 - PubChem
Trilaciclib is an Orally Active CDK4 and CDK6 Inhibitor | MedChemExpress
Trilaciclib Inhibitor CAS No. 1374743-00-6 - Trilaciclib Supplier
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple ...
G1 Therapeutics presents data from Phase 2 mTNBC trial for trilaciclib ...
新型 trilaciclib 类似物的合成和乙酰胆碱酯酶抑制活性,Chemistry & Biodiversity - X-MOL
WO2024009319A1 - Liquid injectable compositions of trilaciclib - Google ...
Real-World Clinical Outcomes of Trilaciclib for the Prevention of ...
Trilaciclib | ≥99%(HPLC) | CDK4/6 inhibitor | AdooQ®
Trilaciclib - LiverTox - NCBI Bookshelf
Trilaciclib cancer drug molecule. 3D rendering. Atoms are represented ...
CAS No : 1374743-01-7 | Product Name : N-Desmethyl Trilaciclib ...
Trilaciclib Protects Against Chemotherapy-Induced Myelosuppression
WO2024165950A1 - Process for preparing trilaciclib or a salt thereof ...
Medchemexpress LLC HY-101467A 5mg , Trilaciclib (hydrochloride) CAS ...
Trilaciclib May Help Protect Against Chemotherapy Damage in Small Cell ...
Investigating potential immune mechanisms of trilaciclib administered ...
Trilaciclib 与咪达唑仑、二甲双胍、利福平、伊曲康唑和拓扑替康在健康志愿者和广泛期小细胞肺癌患者中的药代动力学药物相互作用研究 ...
Evaluating the effectiveness of trilaciclib given before chemotherapy ...
Trial Results Show Trilaciclib Decreases Myelosuppression in Extensive ...
WO2022076779A1 - Solid state forms of trilaciclib and of trilaciclib ...
Trilaciclib for the prevention of chemotherapy-induced myelosuppression ...
Trilaciclib dihydrochloride dihydrate | C24H36Cl2N8O3 | CID 155491232 ...
Trilaciclib hemicitrate | C54H68N16O9 | CID 172866832 - PubChem
Frontiers | The efficacy and safety of Trilaciclib in preventing ...
Trilaciclib plus chemotherapy versus chemotherapy alone in patients ...
Trilaciclib dose selection: an integrated pharmacokinetic and ...
Real‐World Assessment of Trilaciclib for the Prevention of ...
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and ...
Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated ...
trilaciclib | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Trilaciclib prior to chemotherapy and atezolizumab in patients with ...
Trilaciclib | CDK4/6 inhibitor | Anticancer | Chemotherapy | TargetMol
Trilaciclib hi-res stock photography and images - Alamy
Trilaciclib Now Available to Reduce Chemotherapy-Induced Bone Marrow ...
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for ...
Cost-effectiveness analysis of trilaciclib for preventing ...
Trilaciclib fails to extend OS in metastatic triple-negative breast cancer
Exploratory composite endpoint demonstrates benefit of trilaciclib ...
The predictable failure of trilaciclib | ApexOnco - Clinical Trials ...
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell ...
Trilaciclib Cancer Drug Molecule Skeletal Formula Stock Illustration ...
Trilaciclib is a CDK4/6 Inhibitor for Kinds of Cancer Research ...
Trilaciclib | CDK inhibitor | CAS 1374743-00-6 | Selleck
Trilaciclib dihydrochloride | CDK inhibitor | CAS 1977495-97-8 | Selleck
Ciclo de krebs Stock-Vektorgrafiken kaufen - Alamy
Apoptosis Vector Images (over 110)
Proteomic Analysis Reveals Trilaciclib-Induced Senescence - Molecular ...
Simcere Pharmaceutical Group Limited
Slide 11
Slide 18
Slide 17
Slide 39
Slide 20
Slide 27
Slide 40
LOGO
Slide 33
Slide 13
Oncology Letters
Slide 28
Slide 16
slide5
New Drug OK'd for Chemo-Induced Myelosuppression in SCLC | MedPage Today
Slide 36
Synthetic Approaches and Clinical Application of Representative Small ...
trilaciclib治疗小细胞肺癌的新药申请获美FDA优先审查-上市-医保-临床适应症-香港济民药业
Slide 22
Frontiers | Case Report: Analysis of short-term clinical efficacy of ...
FDA批准化疗骨髓保护突破性新药Trilaciclib！先声药业拥有中国权益 - 药时代DrugTimes
slide25
Cosela (Trilaciclib) Injection, 300mg/Vial at ₹ 18000/piece | Injection ...
Trilaciclib, Terapi Pengobatan Baru untuk Kanker Paru-Paru - KlikDokter
The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals ...
Slide 38
Small Cell Lung Cancer Treatment Study by FCS Physicians and Senior Leaders
Synthetic Approaches to Piperazine-Containing Drugs Approved by FDA in ...
COSELA (trilaciclib) for the Treatment of Chemotherapy-Induced ...
短效CDK4/6抑制剂Trilaciclib上市申请已被FDA接受并优先审查|_新浪新闻
A review of trilaciclib, a first-in-class cyclin-dependent kinase 4/6 ...
Dosing | COSELA® (trilaciclib) for injection
盐酸曲拉西利(Trilaciclib Dihydrochloride) - 药物靶点：CDK4 x CDK6_在研适应症：广泛期小细胞肺癌 ...
Proteomic Analysis Reveals Trilaciclib-Induced Senescence - PMC
Synthesis and Acetylcholinesterase Inhibitory Activity of Novel ...
先声药业(02096)与G1骨髓保护新药Trilaciclib快速实现首例患者入组!
盘点：2021年上半年FDA批准的新药医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
两项临床新进展，不一样的CDK4/6抑制剂Trilaciclib医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
FDA批准首个化疗骨髓保护新药Trilaciclib！先声药业拥有中国权益医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
曲拉西利(Trilaciclib)说明书及用法用量-肿瘤药品网
30616-3.jpg)
:format(webp)/article/cGijc5OaGiqJSW7rffWU-/original/071615000_1636629397-Trilaciclib.jpg?w=640&q=100)
